Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy

Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy

PD-L1/PD-1 blockade immunotherapy has significantly improved treatment outcome for several cancer types compared to conventional cytotoxic therapies. However, the specific molecular and cellular mechanisms behind its efficacy are currently unclear. There is increasing evidence in murine models and i...

Full description

Bibliographic Details
Main Authors: Miren Zuazo, Hugo Arasanz, Ana Bocanegra, Gonzalo Fernandez, Luisa Chocarro, Ruth Vera, Grazyna Kochan, David Escors
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Immunology
Subjects:
CD4
immune checkpoint inhibitor
PD-L1
PD-1
biomarker
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2020.586907/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2020.586907/full

Similar Items